Abiopharma

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

Oramed and Lifeward Announce Strategic Transaction

(70% Positive) Dentsply Sirona Inc (XRAY) Files Form 8-K

EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

(99% Neutral) Amneal Pharmaceuticals Inc. (AMRX) Reports Q1 2026 Financial Results

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated <em>Staphylococcus aureus</em> Bacteremia

/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient